These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 23688054)
1. Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer. Cheng D; Kong H; Li Y Biomarkers; 2013 Aug; 18(5):386-90. PubMed ID: 23688054 [TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699 [TBL] [Abstract][Full Text] [Related]
3. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer. Zhang Y; Yu LK; Lu GJ; Xia N; Xie HY; Hu W; Hao KK; Xu CH; Qian Q Asian Pac J Cancer Prev; 2014; 15(19):8435-40. PubMed ID: 25339042 [TBL] [Abstract][Full Text] [Related]
4. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions. Bielsa S; Esquerda A; Salud A; Montes A; Arellano E; Rodríguez-Panadero F; Porcel JM Eur J Intern Med; 2009 Jul; 20(4):383-6. PubMed ID: 19524179 [TBL] [Abstract][Full Text] [Related]
5. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Yeh HH; Lai WW; Chen HH; Liu HS; Su WC Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408 [TBL] [Abstract][Full Text] [Related]
6. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636 [TBL] [Abstract][Full Text] [Related]
7. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Kamide Y; Ishizuka T; Kanai Y; Nakajima T; Mori M Ann Surg Oncol; 2009 Dec; 16(12):3473-81. PubMed ID: 19777189 [TBL] [Abstract][Full Text] [Related]
8. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients. Kozłowski M; Laudański W; Mroczko B; Szmitkowski M; Milewski R; Łapuć G Adv Med Sci; 2013; 58(2):227-34. PubMed ID: 23773968 [TBL] [Abstract][Full Text] [Related]
9. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Wang Q; Diao X; Sun J; Chen Z Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627 [TBL] [Abstract][Full Text] [Related]
10. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676 [TBL] [Abstract][Full Text] [Related]
11. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer? Vicidomini G; Santini M; Fiorello A; Parascandolo V; Calabrò B; Pastore V Ann Thorac Surg; 2005 Jan; 79(1):254-7; discussion 254-7. PubMed ID: 15620952 [TBL] [Abstract][Full Text] [Related]
12. Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study. Gkiozos I; Tsagouli S; Charpidou A; Grapsa D; Kainis E; Gratziou C; Syrigos K Anticancer Res; 2015 Feb; 35(2):1129-37. PubMed ID: 25667503 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer. Sakao Y; Miyamoto H; Yamazaki A; Oh T; Fukai R; Shiomi K; Saito Y Ann Thorac Surg; 2006 Jan; 81(1):292-7. PubMed ID: 16368383 [TBL] [Abstract][Full Text] [Related]
14. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion. Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453 [TBL] [Abstract][Full Text] [Related]
16. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. Seki S; Fujiwara M; Matsuura M; Fujita S; Ikeda H; Asahina I; Ikeda T Oral Oncol; 2011 Jul; 47(7):588-93. PubMed ID: 21602095 [TBL] [Abstract][Full Text] [Related]
17. Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients. Enatsu S; Yoshida J; Yokose T; Nishimura M; Nishiwaki Y; Shirakusa T; Nagai K Ann Thorac Surg; 2006 Jan; 81(1):298-304. PubMed ID: 16368385 [TBL] [Abstract][Full Text] [Related]
18. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721 [TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor expression and neovascularization in non--small cell lung carcinoma. Ozbudak IH; Ozbilim G; Kucukosmanoglu I; Dertsiz L; Demircan A Int J Surg Pathol; 2009 Oct; 17(5):390-5. PubMed ID: 18849317 [TBL] [Abstract][Full Text] [Related]
20. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients. Xu C; Yu L; Zhan P; Zhang Y Eur J Med Res; 2014 May; 19(1):23. PubMed ID: 24887477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]